The company seems to be saying that they have identified genetic biomarkers that will be applicable not just to AD, but also for the Rett and PD trials.
Do you believe that the SIGMAR1 gene in various combinations (like with/without APOE expression) is potentially a common predictor of response in any indication for A2-73?